Menveo

• Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135
• Immunization of high-risk adults and children
• Immunization of persons with asplenia or complement deficiencies
• Immunization of travelers to/residents in hyperendemic/epidemic countries

Adults and Adolescents:

• High-risk: 0.5 mL/dose IM as a single dose
• Asplenia/complement deficiencies: 2 doses (2 months apart), booster every 5 years
• Travel to hyperendemic countries: Single dose

Children:

• 11-12 years: 0.5 mL IM once; booster at age 16 years
• HIV infection: 2-dose primary series (8 weeks apart)
• 2-10 years: Single dose; 2nd dose for high-risk
• 2 months: 4-dose series (2, 4, 6, 12 months)

Children (2 months, 4-dose series):

• Tenderness (24-41%), erythema (11-15%)
• Irritability (42-57%), sleepiness (29-50%)
• Persistent crying (21-41%), change in eating habits (17-23%)
• Vomiting (5-11%), diarrhea (8-16%)

Children (7-23 months, 2-dose series):

• Tenderness (10-16%), erythema (12-15%)
• Irritability (27-40%), sleepiness (17-29%)

Children (2-10 years): Injection site pain (31%), erythema (23%), irritability (18%), headache (11%)

Adolescents & Adults: Injection site pain (41%), headache (30%), myalgia (18%), nausea (10%)

• Caution in Guillain-Barre syndrome
• Preventing and managing allergic vaccine reactions
• Caution in thrombocytopenia or bleeding disorders
• Caution in immunocompromised persons
• Caution in pregnancy and lactation